Clearside Biomedical Inc. (CLSD) Has Soared To A New High On Study Results

Clearside Biomedical Inc. (CLSD) announced Monday morning that its Phase 3 study of suprachoroidal CLS-TA, in patients with macular edema associated with non-infectious uveitis, met its primary endpoint and all of its key secondary endpoints.

from RTT - Hot Stocks http://ift.tt/2FS53gp
via IFTTT